Go Pro
NYSE:LH

Labcorp Q2 2026 Earnings Report

Labcorp logo
$281.85 +2.45 (+0.88%)
Closing price 03:59 PM Eastern
Extended Trading
$282.00 +0.15 (+0.05%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Labcorp EPS Results

Actual EPS
N/A
Consensus EPS
$4.79
Beat/Miss
N/A
One Year Ago EPS
N/A

Labcorp Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.71 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Labcorp Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Thursday, July 30, 2026
Conference Call Time
9:00AM ET

Conference Call Resources

Labcorp Earnings Headlines

Labcorp Holdings: The Story Has Not Changed Materially
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big Tech and Washington policymakers. It can be trucked to a data center, military base, or industrial site and deliver reliable power for years without grid access. A key government milestone expected this August could bring significant visibility to this space. One small stock sits at the center of it.tc pixel
Labcorp Declares Quarterly Dividend
See More Labcorp Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Labcorp? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Labcorp and other key companies, straight to your email.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE:LH) (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services. Its diagnostics offerings include routine and specialty clinical tests, anatomic pathology, molecular and genomic testing, toxicology and companion diagnostics. On the drug development side, the company provides preclinical and clinical research services, central laboratory support, biomarker development, regulatory and commercialization services to pharmaceutical and biotechnology clients.

The company serves a wide range of customers including physicians, hospitals and health systems, biopharmaceutical companies, employers and public health agencies. Labcorp’s operations extend across the United States and into international markets through laboratory facilities, partnerships and service centers, enabling it to support clinical trials and diagnostic needs on a global scale.

Organized to combine diagnostic testing with drug development capabilities, Labcorp has developed integrated service offerings designed to streamline clinical development and accelerate the translation of laboratory findings into clinical and commercial outcomes. As a publicly traded company, it is positioned to leverage laboratory infrastructure, data analytics and scientific expertise to meet evolving needs in healthcare and life sciences.

View Labcorp Profile